BACKGROUND: Buprenorphine/naloxone allows the integration of opioid dependence and HIV treatment. METHODS: We conducted a prospective study in HIV-infected opioid-dependent patients to investigate the impact of buprenorphine/naloxone treatment on drug use. Self-report and chart review assessments were conducted every 3 months (quarters 1-4) for 1 year. Outcomes were buprenorphine/naloxone treatment retention, drug use, and addiction treatment processes. RESULTS: Among 303 patients enrolled between July 2005 and December 2007, retention in buprenorphine/naloxone treatment was 74%, 67%, 59%, and 49% during Quarters 1, 2, 3, and 4, respectively. Past 30-day illicit opioid use decreased from 84% of patients at baseline to 42% in retained patients over the year. Patients were 52% less likely to use illicit opioids for each quarter in treatment (Odds ratio = 0.66; 95% CI: 0.61 to 0.72). Buprenorphine/naloxone doses and office visits approximated guidelines published by the United States Department of Health and Human Services. Urine toxicology monitoring was less frequent than recommended. CONCLUSIONS: Buprenorphine/naloxone provided in HIV treatment settings can decrease opioid use. Strategies are needed to improve retention and address ongoing drug use in this treatment population.
BACKGROUND:Buprenorphine/naloxone allows the integration of opioid dependence and HIV treatment. METHODS: We conducted a prospective study in HIV-infected opioid-dependentpatients to investigate the impact of buprenorphine/naloxone treatment on drug use. Self-report and chart review assessments were conducted every 3 months (quarters 1-4) for 1 year. Outcomes were buprenorphine/naloxone treatment retention, drug use, and addiction treatment processes. RESULTS: Among 303 patients enrolled between July 2005 and December 2007, retention in buprenorphine/naloxone treatment was 74%, 67%, 59%, and 49% during Quarters 1, 2, 3, and 4, respectively. Past 30-day illicit opioid use decreased from 84% of patients at baseline to 42% in retained patients over the year. Patients were 52% less likely to use illicit opioids for each quarter in treatment (Odds ratio = 0.66; 95% CI: 0.61 to 0.72). Buprenorphine/naloxone doses and office visits approximated guidelines published by the United States Department of Health and Human Services. Urine toxicology monitoring was less frequent than recommended. CONCLUSIONS:Buprenorphine/naloxone provided in HIV treatment settings can decrease opioid use. Strategies are needed to improve retention and address ongoing drug use in this treatment population.
Authors: S B Mannheimer; R Mukherjee; L R Hirschhorn; J Dougherty; S A Celano; D Ciccarone; K K Graham; J E Mantell; L M Mundy; L Eldred; Michael Botsko; R Finkelstein Journal: AIDS Care Date: 2006-10
Authors: David A Fiellin; Michael V Pantalon; Marek C Chawarski; Brent A Moore; Lynn E Sullivan; Patrick G O'Connor; Richard S Schottenfeld Journal: N Engl J Med Date: 2006-07-27 Impact factor: 91.245
Authors: Amina A Chaudhry; Michael Botsko; Linda Weiss; James E Egan; Jennifer Mitty; Barbara Estrada; Gregory M Lucas; Tanita Woodson; Timothy P Flanigan; David A Fiellin Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Bruce R Schackman; Jared A Leff; Michael Botsko; David A Fiellin; Fredrick L Altice; P Todd Korthuis; Nancy Sohler; Linda Weiss; James E Egan; Julie Netherland; Jonathan Gass; Ruth Finkelstein Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Linda Weiss; James E Egan; Michael Botsko; Julie Netherland; David A Fiellin; Ruth Finkelstein Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Lynn E Sullivan; Declan Barry; Brent A Moore; Marek C Chawarski; Jeanette M Tetrault; Michael V Pantalon; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin Journal: Clin Infect Dis Date: 2006-12-15 Impact factor: 9.079
Authors: Gregory M Lucas; Amina Chaudhry; Jeffrey Hsu; Tanita Woodson; Bryan Lau; Yngvild Olsen; Jeanne C Keruly; David A Fiellin; Ruth Finkelstein; Patricia Barditch-Crovo; Katie Cook; Richard D Moore Journal: Ann Intern Med Date: 2010-06-01 Impact factor: 25.391
Authors: Lynn E Sullivan; Brent A Moore; Marek C Chawarski; Michael V Pantalon; Declan Barry; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin Journal: J Subst Abuse Treat Date: 2007-10-15
Authors: Jeanette M Tetrault; Janet P Tate; E Jennifer Edelman; Adam J Gordon; Vincent Lo Re; Joseph K Lim; David Rimland; Joseph Goulet; Stephen Crystal; Julie R Gaither; Cynthia L Gibert; Maria C Rodriguez-Barradas; Lynn E Fiellin; Kendall Bryant; Amy C Justice; David A Fiellin Journal: J Subst Abuse Treat Date: 2016-06-06
Authors: Michael S Gordon; Frank J Vocci; Faye Taxman; Marc Fishman; Bikash Sharma; Thomas R Blue; Kevin E O'Grady Journal: Contemp Clin Trials Date: 2019-02-20 Impact factor: 2.226
Authors: David S Metzger; Deborah Donnell; David D Celentano; J Brooks Jackson; Yiming Shao; Apinun Aramrattana; Liu Wei; Liping Fu; Jun Ma; Gregory M Lucas; Marek Chawarski; Yuhua Ruan; Paul Richardson; Katherine Shin; Ray Y Chen; Jeremy Sugarman; Bonnie J Dye; Scott M Rose; Geetha Beauchamp; David N Burns Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731
Authors: Benjamin J Oldfield; Nicolas Muñoz; Mark P McGovern; Melissa Funaro; Merceditas Villanueva; Jeanette M Tetrault; E Jennifer Edelman Journal: AIDS Date: 2019-04-01 Impact factor: 4.177
Authors: Philip T Korthuis; Paula J Lum; Pamela Vergara-Rodriguez; Keith Ahamad; Evan Wood; Lynn E Kunkel; Neal L Oden; Robert Lindblad; James L Sorensen; Virgilio Arenas; Doan Ha; Raul N Mandler; Dennis McCarty Journal: Addiction Date: 2017-02-08 Impact factor: 6.526
Authors: E Jennifer Edelman; Stephen A Maisto; Nathan B Hansen; Christopher J Cutter; James Dziura; Lynn E Fiellin; Patrick G O'Connor; Roger Bedimo; Cynthia Gibert; Vincent C Marconi; David Rimland; Maria C Rodriguez-Barradas; Michael S Simberkoff; Amy C Justice; Kendall J Bryant; David A Fiellin Journal: Contemp Clin Trials Date: 2016-11-20 Impact factor: 2.226
Authors: Kathleen A McGinnis; David A Fiellin; Melissa Skanderson; Yih-Ing Hser; Gregory M Lucas; Amy C Justice; Janet P Tate Journal: Drug Alcohol Depend Date: 2019-09-04 Impact factor: 4.492